

Your Invitation to Attend:

Personalized Medicine for Neuropsychiatric Disorders


AN ASSUREX HEALTH PRESENTATION

PRESENTER

LOCATION

TO REGISTER

RSVP



GeneSight® analyzes how a patient's genes may affect his/her metabolism and response to FDA-approved medicines commonly prescribed to treat neuropsychiatric disorders and chronic pain. The information from the GeneSight test can help clinicians select the medication(s) and dose(s) that are better suited to a patient's condition and genetic makeup. GeneSight can provide an objective and personalized approach to treatment. Four published clinical studies verify the efficacy and utility of GeneSight. Patients whose treatment was guided by GeneSight experienced a 70% greater reduction in depressive symptoms compared to treatment as usual.¹ The GeneSight pharmacogenomic test is developed in the Assurex Health clinical laboratory and is based on patented technology licensed from two world renowned medical centers, Mayo Clinic and Cincinnati Children's Hospital Medical Center, who continue to be research collaborators. In clinical use for more than 5 years, GeneSight has over 8,000 registered healthcare providers and over 80,000 patients who have undergone GeneSight testing.

assurex health | 6030 S. Mason-Montgomery Road
Mason, OH 45040
866.260.2394



©2014 AssureRx Health, Inc.
Assurex Health is a DBA of AssureRx Health, Inc.
Assurex and GeneSight are trademarks of AssureRx Health, Inc.
All rights reserved. Printed in the U.S.A.

www.genesight.com

1. Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA, Drews MS, Eisterhold LL, Geske J, Mrazek DA. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. *Pharmacogenetics and Genomics*. 2013;23(10):535-548.